Shares of BeiGene, a biopharmaceutical company, experienced a pre-market soar of 5.62% on October 4th, 2024. This upward movement in the stock price can be attributed to the company's announcement of granting share options and restricted share units (RSUs) to its employees and directors.
According to filings with the Hong Kong stock exchange, BeiGene granted 22,713 American depositary shares (ADSs), equivalent to 295,269 underlying shares, as share options to 12 employees. These options will vest over a period of 10 years. Additionally, the company granted 90,542 restricted share units in ADSs, equivalent to 1,177,046 underlying shares, to 223 recipients.
The granting of share options and RSUs is a common practice for companies to incentivize and retain their employees and directors. This announcement from BeiGene is seen as a positive signal by investors, reflecting the company's efforts to motivate its workforce and align their interests with those of the shareholders.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。